Developing a new treatment for psoriatic arthritis
Official title: Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation
Funded at Xlock Biosciences, LLC · NIH-10902026 · Data updated 2026-11-12
This study is looking at a new treatment for psoriatic arthritis that targets certain proteins involved in inflammation, with the hope of reducing joint and skin symptoms for people living with this condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xlock Biosciences, LLC NIH-funded |
| Lab location | 1 site (Muskego, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $966,201 |
| NIH project number | 5R44AR081754-02 |
| Project ID | NIH-10902026 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with psoriatic arthritis who experience joint and skin inflammation.
✕Less likely to help
Patients with psoriatic arthritis who do not respond to chemokine-targeted therapies may not benefit from this research.
What this research studies
This research focuses on creating and testing a new therapeutic compound aimed at treating psoriatic arthritis (PsA). It investigates the role of specific chemokines, particularly CCL20 and its receptor CCR6, in driving inflammation associated with PsA. By using engineered proteins that mimic natural molecules, the research aims to reverse the inflammatory processes that lead to joint and skin symptoms. The approach has shown promise in preclinical models, indicating potential effectiveness and safety for patients.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients suffering from psoriatic arthritis.
How similar studies have gone: Previous studies have shown success with similar approaches targeting chemokines in inflammatory diseases, suggesting a promising avenue for treatment.
Where this research is happening
-
Xlock Biosciences, LLC
Muskego, United States Active
Researchers
- Principal investigator: Clarke, William R — Xlock Biosciences, LLC
- Study coordinator: Clarke, William R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.